Entecavir  	Entecavir  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
infection  	infection  	 VBD	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	O
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
entecavir  	entecavir  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
( 	( 	 -LRB-	O
CHB 	CHB 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
adults  	adults  	 NNS	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
five  	five  	 CD	O
randomised  	randomised  	 NNS	B-NP
controlled  	controlled  	 VBN	I-NP
trials  	trials  	 NNS	I-NP
( 	( 	 -LRB-	O
RCTs 	RCTs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
of  	of  	 IN	O
good  	good  	 JJ	O
methodological  	methodological  	 JJ	B-NP
quality  	quality  	 NN	I-NP
and  	and  	 CC	O
measuring  	measuring  	 VBG	O
a  	a  	 DT	O
range  	range  	 NN	O
of  	of  	 IN	O
clinically  	clinically  	 JJ	O
relevant  	relevant  	 JJ	O
outcomes 	outcomes 	 NNS	O
,  	,  	 ,	O
comparing  	comparing  	 VBG	B-NP
entecavir  	entecavir  	 NN	I-NP
with  	with  	 IN	O
lamivudine 	lamivudine 	 NN	B-NP
.  	.  	 .	O
After  	After  	 IN	O
1  	1  	 CD	O
year  	year  	 NN	O
of  	of  	 IN	O
treatment  	treatment  	 NN	B-NP
entecavir  	entecavir  	 NNS	I-NP
was  	was  	 VBD	O
statistically  	statistically  	 RB	O
superior  	superior  	 JJ	O
to  	to  	 TO	O
lamivudine  	lamivudine  	 VB	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
achieving  	achieving  	 VBG	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
virus  	virus  	 NN	I-NP
( 	( 	 -LRB-	O
HBV 	HBV 	 NNP	B-NP
)  	)  	 -RRB-	O
DNA  	DNA  	 NNP	B-NP
suppression 	suppression 	 NN	I-NP
,  	,  	 ,	O
alanine  	alanine  	 FW	B-NP
aminotransferase  	aminotransferase  	 FW	I-NP
( 	( 	 -LRB-	O
ALT 	ALT 	 NNP	B-NP
)  	)  	 -RRB-	O
normalisation  	normalisation  	 NN	B-NP
and  	and  	 CC	O
histological  	histological  	 JJ	B-NP
improvement 	improvement 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
not  	not  	 RB	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
achieving  	achieving  	 VBG	B-NP
hepatitis  	hepatitis  	 NNP	I-NP
B  	B  	 NNP	I-NP
e  	e  	 SYM	I-NP
antigen  	antigen  	 FW	I-NP
( 	( 	 -LRB-	O
HBeAg 	HBeAg 	 NNP	B-NP
)  	)  	 -RRB-	O
seroconversion 	seroconversion 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
or  	or  	 CC	O
serious  	serious  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
for  	for  	 IN	O
both  	both  	 DT	O
treatments 	treatments 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
mixed  	mixed  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
comparison  	comparison  	 NN	I-NP
( 	( 	 -LRB-	O
MTC 	MTC 	 NNP	B-NP
)  	)  	 -RRB-	O
model  	model  	 NN	O
to  	to  	 TO	O
compare  	compare  	 VB	O
entecavir  	entecavir  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
comparator  	comparator  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
in  	in  	 IN	O
nucleoside-naive  	nucleoside-naive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
were  	were  	 VBD	O
considered  	considered  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
uncertain  	uncertain  	 JJ	O
because  	because  	 IN	O
of  	of  	 IN	O
concerns  	concerns  	 NNS	O
over  	over  	 IN	O
its  	its  	 PRP$	O
conduct  	conduct  	 NN	O
and  	and  	 CC	O
reporting 	reporting 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
economic  	economic  	 JJ	B-NP
evaluation  	evaluation  	 NN	I-NP
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
constructed  	constructed  	 VBN	O
two  	two  	 CD	O
Markov  	Markov  	 JJ	B-NP
state  	state  	 NN	I-NP
transition  	transition  	 NN	I-NP
models 	models 	 NNS	I-NP
,  	,  	 ,	O
one  	one  	 CD	O
in  	in  	 IN	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
and  	and  	 CC	O
one  	one  	 CD	O
in  	in  	 IN	O
HBeAg-negative  	HBeAg-negative  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
modelling  	modelling  	 JJ	O
approach  	approach  	 NN	O
was  	was  	 VBD	O
considered  	considered  	 VBN	O
reasonable  	reasonable  	 JJ	O
subject  	subject  	 NN	B-NP
to  	to  	 TO	O
some  	some  	 DT	O
uncertainties  	uncertainties  	 NNS	O
and  	and  	 CC	O
concerns  	concerns  	 NNS	O
over  	over  	 IN	O
some  	some  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
structural  	structural  	 JJ	B-NP
assumptions 	assumptions 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
incremental  	incremental  	 JJ	I-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratios  	ratios  	 NNS	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
entecavir  	entecavir  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
lamivudine  	lamivudine  	 NN	B-NP
and  	and  	 CC	O
pegylated  	pegylated  	 JJ	B-NP
interferon  	interferon  	 JJ	I-NP
alpha-2a  	alpha-2a  	 NN	I-NP
were  	were  	 VBD	O
14,329  	14,329  	 CD	O
pounds  	pounds  	 NNS	O
and  	and  	 CC	O
8403  	8403  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-year  	life-year  	 NN	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Entecavir  	Entecavir  	 NNP	B-NP
was  	was  	 VBD	O
dominated  	dominated  	 VBN	O
by  	by  	 IN	O
telbivudine 	telbivudine 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
HBeAg-negative  	HBeAg-negative  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
ICERs  	ICERs  	 NN	I-NP
for  	for  	 IN	O
entecavir  	entecavir  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
lamivudine 	lamivudine 	 NN	B-NP
,  	,  	 ,	O
pegylated  	pegylated  	 FW	O
interferon  	interferon  	 FW	B-NP
alpha-2a  	alpha-2a  	 FW	I-NP
and  	and  	 CC	O
telbivudine  	telbivudine  	 NNS	B-NP
were  	were  	 VBD	O
13,208  	13,208  	 CD	O
pounds 	pounds 	 NNS	O
,  	,  	 ,	O
7511  	7511  	 CD	O
pounds  	pounds  	 NNS	O
and  	and  	 CC	O
6907  	6907  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
respectively 	respectively 	 RB	O
.  	.  	 .	O
In  	In  	 IN	O
HBeAg-positive  	HBeAg-positive  	 JJ	B-NP
lamivudine-refractory  	lamivudine-refractory  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
entecavir  	entecavir  	 VBP	O
dominated  	dominated  	 VBN	B-NP
adefovir  	adefovir  	 NNS	I-NP
added  	added  	 VBD	O
to  	to  	 TO	O
lamivudine 	lamivudine 	 VB	O
.  	.  	 .	O
In  	In  	 IN	O
one-way  	one-way  	 JJ	B-NP
deterministic  	deterministic  	 JJ	I-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
on  	on  	 IN	O
all  	all  	 DT	O
key  	key  	 JJ	B-NP
input  	input  	 NN	I-NP
parameters  	parameters  	 NNS	I-NP
for  	for  	 IN	O
entecavir  	entecavir  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
lamivudine  	lamivudine  	 NN	B-NP
in  	in  	 IN	O
nucleoside-naive  	nucleoside-naive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
ICERs  	ICERs  	 NNP	B-NP
generally  	generally  	 RB	O
remained  	remained  	 VBN	O
under  	under  	 IN	O
30,000  	30,000  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY 	QALY 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
probabilistic  	probabilistic  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
in  	in  	 IN	O
nucleoside-naive  	nucleoside-naive  	 JJ	B-NP
HBeAg-positive  	HBeAg-positive  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
the  	the  	 DT	O
probability  	probability  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
ICER  	ICER  	 NNP	I-NP
for  	for  	 IN	I-NP
entecavir  	entecavir  	 NNS	I-NP
being  	being  	 VBG	O
below  	below  	 IN	O
20,000  	20,000  	 CD	O
pounds  	pounds  	 NNS	O
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
was  	was  	 VBD	O
57 	57 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
82 	82 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
45 	45 	 CD	O
%  	%  	 NN	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
lamivudine 	lamivudine 	 NN	B-NP
,  	,  	 ,	O
pegylated  	pegylated  	 FW	O
interferon  	interferon  	 FW	B-NP
alpha-2a  	alpha-2a  	 FW	I-NP
and  	and  	 CC	O
telbivudine  	telbivudine  	 VBP	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
In  	In  	 IN	O
nucleoside-naive  	nucleoside-naive  	 JJ	B-NP
HBeAg-negative  	HBeAg-negative  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
the  	the  	 DT	O
probabilities  	probabilities  	 NN	O
were  	were  	 VBD	O
90 	90 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
100 	100 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
96 	96 	 CD	O
%  	%  	 NN	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
lifetime  	lifetime  	 NN	B-NP
treatment  	treatment  	 NN	I-NP
scenario  	scenario  	 NN	I-NP
for  	for  	 IN	I-NP
HBeAg-negative  	HBeAg-negative  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
's  	's  	 POS	O
20-year  	20-year  	 JJ	O
treatment  	treatment  	 NN	B-NP
scenario  	scenario  	 NN	I-NP
for  	for  	 IN	I-NP
HBeAg-positive  	HBeAg-positive  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
increased  	increased  	 VBD	O
the  	the  	 DT	O
ICERs 	ICERs 	 JJ	O
,  	,  	 ,	O
particularly  	particularly  	 RB	O
in  	in  	 IN	O
the  	the  	 DT	O
latter  	latter  	 JJ	O
case 	case 	 NN	O
.  	.  	 .	O
Amending  	Amending  	 VBG	O
the  	the  	 DT	O
HBeAg-negative  	HBeAg-negative  	 JJ	B-NP
model  	model  	 NN	I-NP
so  	so  	 RB	O
that  	that  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
compensated  	compensated  	 JJ	O
cirrhosis  	cirrhosis  	 NN	O
would  	would  	 MD	O
also  	also  	 RB	O
receive  	receive  	 VB	O
lifetime  	lifetime  	 NN	B-NP
treatment  	treatment  	 NN	I-NP
gave  	gave  	 VBD	O
probabilities  	probabilities  	 VBN	O
of  	of  	 IN	O
entecavir  	entecavir  	 NNS	B-NP
being  	being  	 VBG	O
cost-effective  	cost-effective  	 JJ	O
at  	at  	 IN	O
a  	a  	 DT	O
willingness  	willingness  	 NN	O
to  	to  	 TO	O
pay  	pay  	 VB	O
of  	of  	 IN	O
20,000  	20,000  	 CD	O
pounds  	pounds  	 NNS	O
and  	and  	 CC	O
30,000  	30,000  	 CD	O
pounds  	pounds  	 NNS	O
of  	of  	 IN	O
4 	4 	 CD	O
%  	%  	 NN	O
and  	and  	 CC	O
40 	40 	 CD	O
%  	%  	 NN	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
NICE  	NICE  	 NNP	O
guidance  	guidance  	 VBD	O
issued  	issued  	 VBN	O
in  	in  	 IN	O
August  	August  	 NNP	O
2008  	2008  	 CD	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that  	that  	 IN	O
entecavir  	entecavir  	 NN	B-NP
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
option  	option  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
people  	people  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
HBeAg-positive  	HBeAg-positive  	 JJ	I-NP
or  	or  	 CC	O
HBeAg-negative  	HBeAg-negative  	 JJ	B-NP
hepatitis  	hepatitis  	 NN	I-NP
B  	B  	 NN	I-NP
in  	in  	 IN	O
whom  	whom  	 WP	O
antiviral  	antiviral  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
is  	is  	 VBZ	O
indicated 	indicated 	 VBN	O
.  	.  	 .	O
